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Background: Neuronal and glial cell interaction is essential for synaptic homeostasis and may be affected in Alzheimer’s
disease (AD). We measured cerebrospinal fluid (CSF) neuronal and glia markers along the AD continuum, to reveal
putative protective or harmful stage-dependent patterns of activation.
Methods: We included healthy controls (n= 36) and Aβ-positive (Aβ+) cases (as defined by pathological CSF amyloid beta
1-42 (Aβ42)) with either subjective cognitive decline (SCD, n= 19), mild cognitive impairment (MCI, n= 39), or AD dementia
(n= 27). The following CSF markers were measured: a microglial activation marker—soluble triggering receptor expressed
on myeloid cells 2 (sTREM2), a marker of microglial inflammatory reaction—monocyte chemoattractant protein-1 (MCP-1),
two astroglial activation markers—chitinase-3-like protein 1 (YKL-40) and clusterin, a neuron-microglia communication
marker—fractalkine, and the CSF AD biomarkers (Aβ42, phosphorylated tau (P-tau), total tau (T-tau)). Using ANOVA with
planned comparisons, or Kruskal-Wallis tests with Dunn’s pairwise comparisons, CSF levels were compared between clinical
groups and between stages of biomarker severity using CSF biomarkers for classification based on amyloid pathology (A),
tau pathology (T), and neurodegeneration (N) giving rise to the A/T/N score.
Results: Compared to healthy controls, sTREM2 was increased in SCD (p< .01), MCI (p< .05), and AD dementia cases
(p< .001) and increased in AD dementia compared to MCI cases (p< .05). MCP-1 was increased in MCI (p< .05) and AD
dementia compared to both healthy controls (p< .001) and SCD cases (p< .01). YKL-40 was increased in dementia
compared to healthy controls (p< .01) and MCI (p< .05). All of the CSF activation markers were increased in subjects with
pathological CSF T-tau (A+T−N+ and A+T+N+), compared to subjects without neurodegeneration (A−T−N− and A+T−N−).
Discussion: Microglial activation as indicated by increased sTREM2 is present already at the preclinical SCD stage; increased
MCP-1 and astroglial activation markers (YKL-40 and clusterin) were noted only at the MCI and AD dementia stages,
respectively, and in Aβ+ cases (A+) with pathological T-tau (N+). Possible different effects of early and later glial activation
need to be explored.
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Alzheimer’s disease (AD) may be described as a bio-
logical continuum that includes the hallmark patho-
logical processes of amyloid-beta (Aβ) dysmetabolism,
formation of amyloid deposits (A), neurofibrillary tangles
(T), neurodegeneration (N), determined by measuring
cerebrospinal fluid (CSF) levels of Aβ42, phosphorylated
tau (P-tau), and total tau (T-tau) respectively. The pres-
ence or absence of pathological markers can be summa-
rized as an A/T/N score, an unbiased classification of
pathology and severity along the AD continuum [1, 2].
In contrast, the clinical classification of the AD
continuum is based on subjective accounts of cognitive
deficits, performance on cognitive tests, and functioning
in daily life [3–6]. Patients who report experience of
decline in cognitive function while performing within
the normal range on cognitive tests, may be categorized
as having subjective cognitive decline (SCD) [3]. In con-
trast, mild cognitive impairment (MCI) requires the
presence of subjective cognitive decline in combination
with impaired cognitive performance yet retaining pre-
served independence in functional ability [4–6]. We and
others have made large efforts towards standardization
of criteria for these stages, e.g., as part of the EU
JPND-funded BIOMARKAPD study, and Norwegian na-
tional efforts [7, 8].
While genetic evidence indicates that Aβ dysmetabolism
is causal in familial AD, the initial sequence of events and
causality in sporadic AD is still not determined. However,
reduced Aβ clearance and deficient innate immune activ-
ity related to the triggering receptor expressed on myeloid
cells 2 (TREM2) and clusterin (Apo J) function may play a
role [9–11]. While central nervous system (CNS) intersti-
tial Aβ is released from neurons dependent on activity,
clearance is a result of neuronal, astro-, and microglial up-
take and degradation as well as transport to the glympha-
tic system, blood, and (CSF) [12–14]. Microglia normally
subserve synaptic homeostasis and synapse elimination
[15, 16]. They are CNS myeloid-derived innate immune
effector cells, which together with reactive astrocytes also
may acquire inflammatory properties. Genetic evidence
supports a role for loss of balanced TREM2 activation, in-
nate immunity, and microglial activity in AD pathogenesis
[9, 17–19]. Further, experimental studies support neuroin-
flammatory responses as drivers of AD pathogenesis, and
there is evidence for associations to neuroinflammation
and deficient microglia Aβ function in MCI due to AD
and more advanced AD [14, 20–22], though the initial
microglial activation might be compensatory and advanta-
geous. Aβ clearance decreases with age and could in com-
bination with genetic liabilities for compromised innate
immune clearance capacity contribute to age-related dis-
ease inception [23, 24]. Notably, a recent translocator pro-
tein (TSPO) ligand positron-emission tomography (PET)study detecting activated microglia showed higher binding
in AD “slow decliners” [25]. Moreover, a longitudinal
TSPO-PET study demonstrated reduced microglia activa-
tion over time in patients at the MCI stage, but increased
activation in patients at the AD stage of dementia [26].
These findings may be interpreted as an early beneficial
role of microglial activation and a later inflammatory peak.
Experimental evidence suggests that TREM2 increases in
parallel with amyloid deposition, possibly limiting Aβ
plaque-associated pathology [27, 28]. Thus, initial micro-
glial activation might induce phagocytosis of Aβ, stalling
formation of oligomers, and restricting neurotoxicity from
deposited Aβ in plaques, while further inflammatory acti-
vation might accelerate neurodegeneration. If supported,
this distinction could aid patient stratification and guide
intervention trials that include immune modification
components.
Glial activation occurs as part of altered immune cyto-
kine activities, which also change towards increased
inflammatory activity during AD progression. However,
micro- and astroglial activation are interlinked, and gen-
etic evidence suggests that innate immunity could be a
prime mover in the AD cascade [9]. Based on the
described findings of early microglial activation, our
starting point was to investigate these events in CSF
samples via soluble TREM2 (sTREM2) as a microglial
activation marker, and clusterin and chitinase-3-like pro-
tein 1 (YKL-40) which both are suggestive of astroglial
activation, a marker for neuron-microglia communica-
tion (chemokine ligand 1; CX3CL1; fractalkine) and a
well-established marker for microglial mobilization and
inflammatory reaction (monocyte chemoattractant pro-
tein 1, MCP-1).
Soluble TREM2 is released upon microglial activation,
leading to increased levels of CSF sTREM2 in AD [29,
30]. This receptor might subserve Aβ uptake by peptides
being bound to its ligands APOE and clusterin [31–34].
Clusterin is abundantly expressed by astrocytes and
select neuronal populations, e.g., within the hippocam-
pus, and may modulate Aβ metabolism as a chaperone
protein [35]. In binding Aβ, clusterin may increase clear-
ance and inhibit plaque formation in processes that are
coupled to immune responses [35–37]. YKL-40 is pro-
duced mainly by astrocytes, but also microglia, often
surrounding amyloid plaques. While early expression
levels vary, increased expression has been reported at
the MCI stage associated with neuroinflammation [38,
39]. Experimental data suggest a role for YKL-40 in
microglia-astroglia crosstalk [38, 40]. Fractalkine is a
CXC chemokine (CX3CL1) that is highly expressed by
neurons in the hippocampus and cortex, while its recep-
tors (CX3CR1) are found on microglia [41]. Fractalkine
neuron-to-microglia communication strengthens the
neuroprotective role of microglia, by inhibiting TNFα
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microglial activation [43, 44]. The expression level of
fractalkine has been reported to reflect progression of
AD [45]. MCP-1 is a CC chemokine produced by micro-
and astroglia and endothelial cells with receptors
(CCR2) largely restricted to immune cells but also found
on neurons. In the brain, MCP-1 attracts microglial and
peripheral immune cells to sites of inflammation. It may
stimulate microglia to change from resting to activated
morphology, and the level of CSF MCP-1 increases with
advancing pathology in AD [46].
These individual markers have been studied in pre-
dementia and in AD dementia stages with variable re-
ported findings (see Additional file 1: Table S1). To
our knowledge, none of the included CSF immune
markers (sTREM2, MCP-1, YKL-40, fractalkine, and
clusterin) have been studied in a defined SCD group;
however, both CSF sTREM2 and YKL-40 have been
studied in preclinical AD (SCD cases and asymptom-
atic subjects) with pathological (low) CSF Aβ. Neither
sTREM2 nor YKL-40 was reportedly increased in this
mixed group [29, 30, 38, 40]. Clusterin and fractalkine
have been little studied in MCI [47, 48], but sTREM2,
MCP-1, and YKL-40 have all shown contradictory re-
sults, either unchanged [49–52] or increased [29, 30,
38, 40, 53, 54] compared to controls. Except for
YKL-40 [38, 51] and fractalkine [47] which respect-
ively have been found unchanged or reduced com-
pared to controls, all the other immune markers have
shown contradictory results in AD dementia com-
pared to controls, either unchanged [29, 49, 51,
55–59], reduced [60, 61], or increased CSF values [38,
50, 53, 54, 62–65].
Intrathecal levels of glial- and inflammation markers
may reflect both CNS AD pathogenic processes and
responsivity, as well as inflammatory reactivity upon
stimulation such as therapeutic interventions and infec-
tious agents. To our knowledge, CSF sTREM2, MCP-1,
YKL-40, clusterin, and fractalkine have never been ana-
lyzed in the same cohorts across predementia AD stages.
Thus, we currently lack information on putative disparate
or concerted micro- and astroglial patterns of activation
and inflammation related to clinical and neuropathological
changes in predementia AD. As activation may be bi- or
multiphasic along the AD continuum, highly standardized
protocols and measurements on standardized platforms,
tightly controlled clinical staging, and biomarker-based
stratification may be necessary to detect relevant
differences.
Microglial activation per se does not need to be in-
flammatory, but may be a compensatory response at the
synapse. Following Fan et al. [26], we hypothesize that
the earliest stage of demonstrable microglial activation
occurs at the pre-clinical stage, only coincident withother inflammatory and astroglial activation markers at
later stages. We also explore relations between CSF
biomarker-derived A/T/N stages and glial activation
markers.Methods
Subjects
For the purposes of the present study, we selected 121
participants from two Norwegian cohorts. Healthy con-
trols with normal CSF (n = 36), participants with SCD
(n = 18), and MCI (n = 20) patients, both with CSF Aβ42
confirmed amyloid pathology, were selected from the
Norwegian multicenter study, “Dementia Disease Initi-
ation” (DDI) [7]. A patient group meeting the National
Institute on Aging–Alzheimer’s Association (NIA-AA)
criteria for dementia due to AD [6] (n = 27) and an
additional 19 MCI patients with CSF Aβ42 confirmed
amyloid pathology were included from the Norwegian
part of the Gothenburg-Oslo MCI (MCI-GO) cohort
[66]. Classification of A/T/N groups [1] was done using
CSF Aβ42 (A), phosphorylated tau (P-tau) (T), and
total-Tau (T-tau) (N). All subjects were assigned binary
scores for each category, rated positive when the CSF
biomarker value was defined as pathological. The cut-off
for CSF was Aβ42 < 708 pg/ml for amyloid plaque path-
ology, subsequently denoted Aβ-positive (Aβ+) and A+
cases. This Aβ optimal cut-off was determined by a PET
[18F]-Flutemetamol uptake study [67]. Cases with Aβ42
values close to cutoff (± 30 ng/ml) were excluded from
this study material. The abnormality cut-off values for
CSF T-tau and P-tau were set in accordance with refer-
ence values from Sjögren et al. [68]. For P-tau, the
cut-off value was ≥ 80 pg/ml, and values above this
threshold were classified as a T+ score. For T-tau,
cut-off values were > 300 pg/ml for age < 50 years, > 450
pg/ml for age 50–69 years, and > 500 pg/ml for age ≥ 70
years. Subjects were denoted N+ cases when their T-tau
value exceeded the respective thresholds.
Further criteria for inclusion were age between 40 and
80 years and a native language of Norwegian, Swedish,
or Danish. Exclusion criteria were brain trauma or disor-
ders, including clinical stroke, dementia, severe psychi-
atric disorder, and severe somatic disease that might
influence the cognitive functions, intellectual disability,
or other developmental disorders.
Both DDI and MCI-GO employ a standardized proto-
col for participant selection, assessment, and disease
stage classification according to published criteria [3, 4,
6]. All patients were interviewed and examined by a
physician trained in diagnosing cognitive disorders. They
all underwent cognitive testing, either cerebral MRI or
CT, blood screening, and standard lumbar puncture as
part of the clinical assessment.
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Participants were classified as SCD according to the
SCD-I framework, which requires normal objective
cognitive performance on neuropsychological tests
while experiencing a subjective decline in any cognitive
domain [3]. MCI was classified according to the
NIA-AA criteria which require the presence of subject-
ive cognitive impairment or decline in combination
with lower performance than expected in one or more
cognitive domains, yet preserved independence in func-
tional ability and not fulfilling the criteria of dementia
[4, 6]. Performance was classified as normal or abnor-
mal according to published norms (adjusted for age,
sex, and educational effects) for the different tests
[69–71]. Due to mutually exclusive criteria, the cut-off
values for SCD vs. MCI (defined as normal or abnormal
cognition) were ≤ 1.5 standard deviation below norma-
tive mean on either Consortium to Establish a Registry
for AD (CERAD) word list (delayed recall), Visual
Object and Space Perception (VOSP) silhouettes, Trail
Making Test part B (TMT-B), or Controlled Oral Word
Association Test (COWAT). For the DDI cohort global
cognitive status was also assessed by the Clinical
Dementia Rating Scale (CDR), whereas the Global
Deterioration Scale was used for MCI-GO [72, 73].
CSF collection and handling
Lumbar punctures were performed similarly on four
sites all following a detailed BIOMARKAPD SOPs as
described previously [8]. Briefly described, sampling was
done before noon and CSF was collected in polypropyl-
ene tubes (Thermo Fisher Scientific, MA, USA) which
were centrifuged within 4 h at 2000g for 10 min at room
temperature. The supernatant was subsequently trans-
ferred to new defined tubes, directly frozen at − 80 °C on
site and kept at − 80 °C until thawed for analysis. All
CSF samples were analyzed either at the Department of
Interdisciplinary Laboratory Medicine or Section of
Clinical Molecular Biology (EpiGen) at Akershus Univer-
sity Hospital. The exception was the sTREM2 analysis,
which was assayed at the Department of Pharmacology
at the University of Oslo.
Protein biomarker measurements
Commercial enzyme-linked immunosorbent assays (ELI-
SAs) based on monoclonal antibodies were used to
measure CSF levels of the following protein biomarkers:
Aβ42, T-tau, and P-tau. They were determined using
Innotest β-Amyloid (1-42), Innotest T-tau Ag, and
Innotest P-tau (181P)(Fujirebio, Ghent, Belgium),
respectively.
CSF sTREM2 was also analyzed using a sandwich
ELISA as described earlier [49] with some modifications;
the plates were coated over night with the captureantibody (0.25 μg/ml; AF1828, R&D Systems, MN, USA)
and samples incubated for 2 h prior to TREM2 detection
with a rabbit-monoclonal anti-human TREM2 antibody
(0.5 μg/ml; SEK11084, Sino Biologics, Beijing, China).
The QuickPlex SQ 120 system from Meso Scale Dis-
covery (MSD, MD, USA) was used to measure YKL-40,
MCP-1, and fractalkine in a U-plex format and clusterin
in an R-plex format, where YKL-40 and clusterin were in
a singleplex setup and MCP-1 and fractalkine were in
the same multiplex setup. The MSD analyses were car-
ried out according to the manufacturers’ procedures,
with the adjustments that CSF samples were diluted 200
times prior to YKL-40 and clusterin analyses, and the
multiplex setup was used with 100 μl neat CSF and 25 μl
buffer.
All the lower limits of quantifications (LLOQs) were
defined as the lowest concentration at which the coeffi-
cient of variation (CV) of the calculated concentration
was < 20% in > 75% of the analyses or the mean CV was
< 20% in our test set. All biomarker values in all samples
were well above LLOQ. All samples were analyzed in
duplicates and reanalyzed if relative deviations (RDs)
exceeded 20%. In addition, quality control samples with
RD threshold of 15% assured inter-plate and inter-day
variation.
Statistical analysis
Normality was assessed through the inspection of
Q-Q plots, histograms, and the Shapiro-Wilks test of
normality.
In order to explore and adjust for age and sex, and
APOE-ɛ4 allelic effects on CSF inflammatory markers
in healthy aging, simple and multiple regression
analyses (controlling for several covariates) were per-
formed between these variables and CSF immune
markers within the healthy control group. If a signifi-
cant relationship was observed between these covari-
ates and an inflammatory marker in the healthy
control group, the standardized residuals from the
pertinent regression model was obtained for the
entire sample and used in further analysis in order to
adjust for these covariates in between-group compari-
sons. To assess differences in biomarker levels
between groups, we performed one-way ANOVAs
with planned comparisons for variables with normal
distributions. We performed Kruskal-Wallis test with
Dunn’s non-parametric pairwise post hoc test with
Bonferroni corrections to assess group differences in
variables with non-normal distributions (CSF Aβ42,
CSF T-tau, CSF P-tau, MMSE, and A/T/N groups).
Non-parametric pairwise comparisons and ANOVA
contrasts were performed in a hierarchical manner.
We compared Aβ + SCD, MCI, and AD dementia
groups to healthy controls, and finally we compared
Nordengen et al. Journal of Neuroinflammation           (2019) 16:46 Page 5 of 13the SCD with the MCI group and both SCD and MCI
to the AD dementia group. The dichotomous variable
“sex” was assessed using a chi-square test. For the A/
T/N groups, A−T−N− and A+T−N− were compared
to all other groups. Only one patient had A+T+N−
classification, and this patient was excluded from
both statistical analysis and figure.
To assess clinical stage dependent relationships
between the innate immune response to AD path-
ology, correlational analyses between the inflammatory
markers (sTREM2, YKL40, MCP-1, fractalkine, and
clusterin) and CSF AD biomarkers (Aβ42, T-Tau, and
P-tau) were performed using Pearson’s r within the
pertinent symptomatic groups (SCD, MCI, and AD
dementia).
All analyses were performed in the Statistical Package
for Social Sciences (SPSS) version 25, and the signifi-
cance level was defined as p < .05.Ethics
The regional medical research ethics committee approved
this study. Participants gave their written informed
consent before taking part in the study. All further study
conduct was in line with the guidelines provided by the
Declaration of Helsinki (1964; revised 2013) and the Nor-
wegian Health and Research Act (2009).Results
See Table 1 for further characterization of the study
cohort.The mean concentration and standard deviations
for sTREM2, MCP-1, YKL-40, fractalkine, and clusterin
at the different clinical stages are shown in Table 2.Age, sex, and APOE-ɛ4 allelic relationship with CSF
immune markers in healthy controls
Neither APOE-ɛ4 status nor sex was associated with any
of the CSF inflammatory markers in healthy controls
when using simple regression analysis. When age and
CSF T-tau were included in multiple regression models,
both age (β = .477, p < .001) and T-tau (β = .384, p < .01)
were shown to predict CSF YKL-40 (adjusted R2 = .497,
F[2, 33] = 18.280, p < .001) (Additional file 2). The same
was not true for CSF sTREM2, where the relationship
between age and sTREM2 was not found in healthy con-
trols (β = .248, p = n.s.), when controlling for the effects
of T-tau (β = .478, p < .01) in a multiple regression ana-
lysis (adjusted R2 = .342, F[2, 32] = 9819, p < .001). No
relationships were found between age and CSF MCP-1,
clusterin, or fractalkine within the healthy control group
in any regression models. Thus, only YKL-40 was ad-
justed for age-effect prior to analysis of between-group
differences in clinical staging.CSF activation and inflammation marker comparisons
based on clinical staging
CSF level comparisons between clinical groups are sum-
marized in Table 2, illustrated in Fig. 1, and further com-
pared in Additional file 3: Figure S2. CSF sTREM2,
YKL-40, and MCP-1 were increased at more advanced
clinical stages, but differed according to which cognitive
stage they showed abnormal levels.
CSF sTREM2 values were higher in Aβ + SCD subjects
(t(116) = 3.282, p < .01), Aβ +MCI subjects (t(116) = 2.364,
p < .05), and subjects with AD dementia (t(116) = 4.213,
p < .001), compared to healthy controls. A higher CSF
sTREM2 level was also found in subjects with AD dementia
compared to Aβ +MCI subjects (t(116) = 2.135, p < .05).
No difference in the CSF YKL-40 level was found
between healthy controls, and Aβ + SCD or Aβ +MCI
subjects. However, an increased level of CSF YKL-40
was found in subjects with AD dementia compared to
both Aβ +MCI subjects (t(117) = 2.370, p < .05) and
healthy controls (t(117) = 3.096, p < .01).
No differences in CSF MCP-1 levels were demon-
strated between Aβ + SCD and healthy controls. How-
ever, CSF MCP-1 levels were equally increased in Aβ +
MCI subjects and subjects with AD dementia, and levels
where higher in these groups compared to healthy
controls ((t(117) = 2.480, p < .05) and (t(117) = 3.704,
p < .001) respectively).
Finally, no significant differences between clinical
groups were found for either CSF fractalkine or CSF clus-
terin. The between-group ANOVA analysis for clusterin
was, however, borderline significant (F(3, 117) = 2.574,
p = .057), with markedly higher CSF clusterin levels in the
dementia group compared to the control group (Fig. 1).CSF activation and inflammation marker comparisons
based on A/T/N biomarker classification
CSF level comparisons between A/T/N groups are illus-
trated in Fig. 2.
No differences in CSF sTREM2, YKL-40, MCP-1, or
CSF clusterin levels were found between healthy controls
with normal CSF (A−T−N− n = 36) compared to partici-
pants with cognitive symptoms with A+T−N− (n = 23).
However, the levels of these markers were all equally
increased in A+T−N+ (n = 30) and A+T+N+ (n = 31),
p < .01–p < .001 and p < .05–p < 01 respectively, please
see Table 1 and Fig. 2 for details. Within the SCD group,
there were no significant differences between those with
pathological levels of T-tau and/or P-tau (n = 9) and
those with normal CSF levels, for either CSF sTREM2,
YKL-40, MCP-1, clusterin, or fractalkine (independent
samples T-test), nor no significant correlations between
CSF MCP-1 or clusterin and T-tau or P-tau. However,
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Fig. 1 Between-group CSF immune marker comparisons based on clinical staging. Fig. text: The Y-axis with sTREM2 (a), MCP-1 (b), fractalkine (d), and
clusterin (e) reported as CSF concentration in nanograms per milliliter, while the Y-axis for YKL-40 (c) are residuals standardized for age. Error bars are
shown as mean and 95% confidence interval (CI). Abbreviation: Ctr: healthy controls (n = 36), SCD: CSF Aβ42+ subjects with subjective cognitive
decline (n = 19), MCI: CSF Aβ42+ subjects with mild cognitive impairment (n = 39), Dem: Aβ42+ subjects with Alzheimer’s disease dementia (n = 27).
Statistically significant differences are marked with asterisks, where * indicates p < .05, ** indicates p < .01, and *** indicates p < .001
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P-tau within the SCD group (Table 3).
CSF fractalkine was increased in A+T−N+ (n = 30)
and A+T+N+ (n = 31) compared to patients with
pathological CSF Aβ without tau pathology or neuro-
degeneration markers A+N−T− (n = 23) (p < .001 and
p < .01 respectively), in accordance with the associ-
ation between fractalkine and T-tau (Table 3). CSF
fractalkine was lower (1603 ng/ml, SD 345) in A+T−N
− than in A−T−N− healthy controls (1823 ng/ml, SD
446), but this difference did not reach statistical sig-
nificance (p = .057). CSF clusterin levels were equally
increased in both A+T−N+ (n = 30) and A+T+N+(n = 31) compared to healthy controls with normal
CSF (A−T−N−, n = 36) (p < .01 and p < .05 respect-
ively) and also in accordance with the association
with T-tau (Table 3).
There were no significant correlations between
sTREM2, YKL-40, MCP-1, or fractalkine and CSF
Aβ42 in our cohort, neither in subgroups controlled
separately nor when all symptomatic subjects were
combined. There was, however, a correlation between
CSF clusterin and CSF Aβ42 (β = 0.568, p < 0.05) in
the SCD group. CSF T-tau correlated strongest with
all of the before mentioned activation markers when
all symptomatic subjects were combined, in addition
Fig. 2 Between-group CSF immune marker comparisons based on ATN staging. Fig. text: The association with ATN groups. Y-axis shows concentration
of inflammatory markers in CSF in nanograms per milliliter. A+ indicating CSF Aβ42 below the reference range, T+ indicating CSF p-tau above the
reference range and N+ here indicating T-tau above the reference range for age. Minus (−) indicating normal values within the reference range. Error
bars are shown as mean and 95% confidence interval (CI). Statistically significant differences are marked with asterisks, where * indicates p < .05, **
indicates p < .01, and *** indicates p < .001
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Table 3.
Discussion
In this study, we have demonstrated microglial activa-
tion in Aβ + SCD cases, as shown by increased
sTREM2. Since there were no differences in objective
cognitive performance between the healthy controls
and the SCD group (see Table 1), increased CSF
sTREM2 in the Aβ + SCD group suggests microglial
activation even before objective cognitive decline.
Furthermore, we did not find evidence for neitherastroglial activation at this stage (no significant
increase of YKL-40 or clusterin) nor for a microglial
inflammatory response (no significant increase in
MCP-1 levels). CSF MCP-1 levels were increased in
the Aβ + MCI group compared to healthy controls, in-
dicative of an inflammatory response at the MCI
stage. This interpretation is corroborated by the
increase in astroglial markers at the dementia stage,
indicative of involvement of astrocytes in the inflam-
matory process as loss of cognitive abilities progresses
even further. These differences may represent func-
tionally important stages of innate immune activation
Table 3 Correlation analyses between inflammatory and AD CSF biomarkers by diagnostic category
All symptomatic subjects (SCD, MCI, AD dementia) (n = 85)
Variable CSF sTREM2 CSF YKL-40 CSF MCP-1 CSF Fractalkine CSF Clusterin
CSF Aβ42 n.s. n.s. n.s. n.s. n.s.
CSF T-tau .318, p < .01 .589, p < .001 .276, p < .05 .507, p < .001 .400, p < .001
CSF P-tau .289, p < .01 .444, p < .001 n.s. .368, p < .001 .290, p < .01
SCD (n = 18)
Variable CSF sTREM2 CSF YKL-40 CSF MCP-1 CSF Fractalkine CSF Clusterin
CSF Aβ42 n.s. n.s. n.s. n.s. .568, p < .05
CSF T-tau .629, p < .01 .730, p < .001 n.s. .616, p < .01 n.s.
CSF P-tau .655, p < .01 .679, p < .01 n.s. .536, p < .05 n.s.
MCI (n = 40)
Variable CSF sTREM2 CSF YKL-40 CSF MCP-1 CSF Fractalkine CSF Clusterin
CSF Aβ42 n.s. n.s. n.s. n.s. n.s.
CSF T-tau n.s. .409, p < .01 n.s. .479, p < .01 .330, p < .05
CSF P-tau .335, p < .05 .347, p < .05 n.s. .375, p < .05 .364, p < .05
AD dementia (n = 29)
Variable CSF sTREM2 CSF YKL-40 CSF MCP-1 CSF Fractalkine CSF Clusterin
CSF Aβ42 n.s. n.s. n.s. n.s. n.s.
CSF T-tau n.s. .660, p < .001 n.s. .550, p < .01 .415, p < .05
CSF P-tau n.s. .439, p < .05 n.s. n.s. n.s.
Reported values are Pearson’s r and associated p value
n.s. non-significant (p > .05)
Nordengen et al. Journal of Neuroinflammation           (2019) 16:46 Page 9 of 13and neuroinflammation along the AD continuum and
are summarized in Additional file 3: Figure S2.
Increasing inflammation with increasing
neurodegeneration, but not Aβ pathology alone
All of the inflammatory markers were increased in CSF
in subjects with pathological T-tau (A+T−N+ and A+T
+N+), indicating neurodegeneration, compared to those
subjects without neurodegeneration (A−T−N− and A+T
−N−). Interestingly, neither glial activation markers nor
inflammatory markers were significantly increased in
cases with only Aβ+ pathology (A+T−N−) compared to
healthy controls (A−T−N−), though CSF fractalkine
showed a non-significant reduction. For both CSF frac-
talkine and CSF clusterin, the increase with increasing
neurodegeneration may be masked when comparing the
clinical groups, as these contain subjects with and with-
out neurodegeneration, but it became evident when we
employed the A/T/N classification. For CSF fractalkine,
we found no between group differences between the
control group/A−T−N− compared to the other clinical
groups. However, when comparing A/T/N groups as a
measure of AD biomarker severity, the Aβ42-positive
group without neurodegeneration (A+T−N−, 13 subjectswith MCI and 9 with SCD) showed significantly lower
CSF fractalkine levels compared to the Aβ42-positive
groups with neurodegeneration (A+T−N+, 1 SCD sub-
ject, 10 MCI subjects, and 19 AD dementia, and A+T+N
+, 7 SCD subjects, 16 MCI subjects, and 8 AD demen-
tia). CSF fractalkine showed a clear association to T-tau
in all clinical subgroups, see Table 3. Moreover, CSF
clusterin was also associated with T-tau in both the MCI
and dementia subgroups, but not the SCD group. While
the between-group ANOVA analysis for clusterin did
not reach the threshold for statistical significance, the
dementia group did show markedly higher levels com-
pared to the control group. This negative result may
have been due to the inclusion of a heterogeneous sam-
ple with relatively small subgroups. When our cohort
was categorized according to the A/T/N biomarker
classification scheme, however, the difference between
the groups without (A−T−N− and A+T−N−) and those
with neurodegeneration (A+T−N+ and A+T+N+) was
clearly evident (Fig. 2). Thus, findings relative to clinical
and A/T/N stages are in general accordance, both
consistent with a restricted microglial activation accom-
panying amyloid pathology (A+) without more extensive
inflammatory activation, the latter accompanying
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ment at the MCI and dementia stages.
Our findings in the clinical stages are in accordance
with imaging data suggestive of a biphasic microglial
response, though the sTREM2 level in our material at
the SCD stage was only nominally higher but not signifi-
cantly different from that at the MCI stage [25, 26].
Aging is associated with subtle microglial priming, facili-
tating phagocytosis and homeostatic recovery but also
further development of potentially detrimental inflam-
matory properties that may increase Aβ and tau patholo-
gies [74, 75]. A sequence of events is not established, as
microglia may be primed by several types of stimuli
including Aβ, but our description of the relation be-
tween inflammatory and neurodegeneration markers is
consistent with the above description.
Our findings may help interpret studies of immunomo-
dulating therapies towards reducing the Aβ deposition by
increasing the microglial clearance [76]. A too advanced
stage of AD may have contributed to trial failures with sev-
eral phase III studies being discontinued due to lack of
treatment efficacy or side effects. Cerebral Aβ aggregation
starts 10 to 15 years before mild cognitive decline [77] and
20 to 30 years before dementia onset [78]. The present
findings suggest that the innate immune system and astro-
glial cells may undergo sequential changes towards an in-
flammatory activation also during the preclinical part of
this period, represented by sTREM2 and YKL-40, respect-
ively. Immunomodulating therapies might have different
effects depending on the state of immune activation, i.e.,
whether monocyte and astroglial inflammatory components
are activated or not [26]. Thus, immune activation should be
investigated in greater detail by analyzing CSF markers pro-
and anti-inflammatory markers throughout the AD con-
tinuum, which we plan to explore in a subsequent study.
A limitation of these findings is that these markers are
expressed or secreted by multiple cell types and are not
completely specific to neuronal, microglial, or astrocyte
expression. Fractalkine is mainly expressed on neurons
in the CNS [79], but expression is also seen in astrocytes
[80], especially in neuroinflammatory models [81–83].
Also, the choroid plexus has been shown to express frac-
talkine in experimental activation models [84]. MCP-1 is
expressed by astrocytes [85, 86], microglia [87] and neu-
rons [88]. YKL-40 is primarily expressed by astrocytes
and to a lesser degree by microglia [89]. Although clus-
terin is mainly expressed by astrocytes [90–93], and
especially reactive astrocytes [94], expression has also
been shown in neurons [92–95] and degenerating oligo-
dendrocytes [91]. TREM2, on the other hand, seems to
be specific to microglia in the brain [96–99]. However,
in peripheral tissue, TREM2 has been shown to be
expressed by several myeloid cells, including tissue mac-
rophages and dendritic cells [100].In addition to a relatively small sample size, a further
limitation in this work is the cross-sectional design, as
longitudinal sampling is necessary for a better interpret-
ation of the sequence of events along the AD con-
tinuum. Furthermore, a more extensive mapping of
inflammatory cytokine markers will be needed.
Conclusion
We here demonstrate increased microglial activation at a
preclinical AD stage, with increased CSF sTREM2 levels in
Aβ+ SCD. The MCP-1 level was significantly enhanced at
the Aβ+MCI stage, and CSF YKL-40 in AD dementia, sug-
gesting a shift towards a more harmful stage of immune
activation as AD progresses. Furthermore, our findings sug-
gest that inflammation is associated with neurodegeneration,
but not with amyloid pathology alone.
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